Study of Cizutamig for Hard-to-Treat Rheumatoid Arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests an experimental drug called cizutamig for people with rheumatoid arthritis that hasn't responded to other treatments. It aims to see if a new approach can help control the disease in patients who still have active inflammation despite trying other advanced therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with moderate to severe active rheumatoid arthritis
- You tested positive for rheumatoid factor (RF) or anti-CCP antibodies
- You have tried at least one targeted or biologic DMARD and it didn't work well enough or caused side effects
- You do not have any active infections, other autoimmune diseases, or certain other health conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't been controlled by multiple standard treatments. It aims to see if telitacicept can help reduce inflammation and improve symptoms.
This trial tests an investigational drug called JAB-8263 for people with active rheumatoid arthritis. It aims to see if the drug can help reduce inflammation and improve symptoms.
This early-stage study tests a new injectable medicine (KT501) for people with moderate to severe rheumatoid arthritis who have not responded well enough to other treatments and have specific antibodies in their blood. It aims to see how safe and well-tolerated the drug is.
This study tests a new biologic drug called cizutamig for people with active lupus (SLE) who haven't gotten enough help from standard treatments. The goal is to see if it can safely reduce disease activity.
This trial tests an experimental drug called Cizutamig to see if it can help people with systemic sclerosis (SSc), a condition that causes skin thickening and organ problems. You may qualify if you have had SSc for 7 years or less and your skin score is at least 15.
This trial tests an investigational drug called cizutamig for people with generalized myasthenia gravis (gMG) whose symptoms are not well controlled by current treatments. The goal is to see if it can improve daily activities.
Hear when a new Rheumatoid Arthritis (RA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.